Table 2.

Clinicopathological characteristics of patients with α-internexin methylation

Demographic and Clinical Characteristics		N	%
GEP-NENs (n = 116)
Sex	Male	72	62.1
	Female	44	37.9
Age (years) at diagnosis	≤50	50	43.1
	> 50	66	56.9
	Median (range)	55 (16–83)
Functional status	Nonfunctional	89	76.7
	Functional	27	23.3
	Insulinoma	26	22.4
	Gastrinoma	1	0.9
Tumor location	Gastrointestinal tract	54	46.6
	Stomach	18	15.5
	Rectum	10	8.6
	Duodenum	10	8.6
	Esophagus	10	8.6
	Colon	4	3.4
	Jejunum/ileum	2	1.7
	Pancreas	49	42.2
	Other	13	11.2
	Metastasis of unknown primary	10	8.6
	Biliary tract	3	2.6
Tumor gradea	G1	41	36.3
	G2	23	20.4
	G3	49	43.4
Tumor typea	NET	64	56.6
	NET G1	41	36.3
	NET G2	23	20.4
	NEC	43	38.1
	MANEC	6	5.3
Tumor stage	I	27	23.3
	II	35	30.2
	III	28	24.1
	IV	26	22.4
GI-NENs (n = 54)
Tumor gradeb	G1	8	15.4
	G2	7	13.5
	G3	37	71.2
Tumor typeb	NET	15	28.8
	NET G1	8	15.4
	NET G2	7	13.5
	NEC	33	63.5
	MANEC	4	7.7
Tumor stage	I	5	9.3
	II	14	25.9
	III	23	42.6
	IV	12	22.2
pNENs (n = 49)
Tumor gradec	G1	32	66.7
	G2	11	22.9
	G3	5	10.4
Tumor typec	NET	43	89.6
	NET G1	32	66.7
	NET G2	11	22.9
	NEC	5	10.4
	MANEC	0	0
Tumor stage	I	22	44.9
	II	20	40.8
	III	1	2.0
	IV	6	12.2

^a 113 cases both for tumor grade and tumor type; ^b 52 cases both for tumor grade and tumor type; ^c 48 cases both for tumor grade and tumor type

GEP-NEN: Gastroenteropancreatic neuroendocrine neoplasm; NET: Neuroendocrine tumor; NEC: Neuroendocrine carcinoma; MANEC: Mixed adenoneuroendocrine carcinoma; GI-NEN: Gastrointestinal neuroendocrine neoplasm; pNEN: Pancreatic neuroendocrine neoplasm